Aché Laboratórios Farmacêuticos S.A., Guarulhos, São Paulo 07034-904, Brazil.
Centro de Química Medicinal, Centro de Biologia Molecular e Engenharia Genética, Universidade Estadual de Campinas, Av. Dr. André Tosello 550, 13083-886 Campinas, São Paulo Brazil.
J Med Chem. 2024 Jun 13;67(11):8609-8629. doi: 10.1021/acs.jmedchem.3c02250. Epub 2024 May 23.
Vaccinia-related kinase 1 (VRK1) and the δ and ε isoforms of casein kinase 1 (CK1) are linked to various disease-relevant pathways. However, the lack of tool compounds for these kinases has significantly hampered our understanding of their cellular functions and therapeutic potential. Here, we describe the structure-based development of potent inhibitors of VRK1, a kinase highly expressed in various tumor types and crucial for cell proliferation and genome integrity. Kinome-wide profiling revealed that our compounds also inhibit CK1δ and CK1ε. We demonstrate that dihydropteridinones and mimic the cellular outcomes of VRK1 depletion. Complementary studies with existing CK1δ and CK1ε inhibitors suggest that these kinases may play overlapping roles in cell proliferation and genome instability. Together, our findings highlight the potential of VRK1 inhibition in treating p53-deficient tumors and possibly enhancing the efficacy of existing cancer therapies that target DNA stability or cell division.
痘苗病毒相关激酶 1(VRK1)和酪蛋白激酶 1 的 δ 和 ε 同工型(CK1)与各种与疾病相关的途径有关。然而,这些激酶缺乏工具化合物,极大地阻碍了我们对其细胞功能和治疗潜力的理解。在这里,我们描述了基于结构的 VRK1 抑制剂的开发,VRK1 是一种在各种肿瘤类型中高度表达的激酶,对细胞增殖和基因组完整性至关重要。激酶组全谱分析显示,我们的化合物还抑制 CK1δ 和 CK1ε。我们证明二氢喋啶酮和模拟 VRK1 耗竭的细胞结果。与现有 CK1δ 和 CK1ε 抑制剂的互补研究表明,这些激酶在细胞增殖和基因组不稳定性中可能发挥重叠作用。总之,我们的研究结果强调了抑制 VRK1 在治疗 p53 缺陷型肿瘤中的潜力,并可能增强针对 DNA 稳定性或细胞分裂的现有癌症疗法的疗效。